Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results.

[1]  A. Fortin,et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[2]  A. Zietman,et al.  Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. , 1996, Urology.

[3]  G. Duchesne,et al.  Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  M. Gleave,et al.  Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. , 1996, The Journal of urology.

[5]  A. Zietman,et al.  The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. , 1995, International journal of radiation oncology, biology, physics.

[6]  T. Schultheiss,et al.  Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. , 1995, International journal of radiation oncology, biology, physics.

[7]  M. Gleave,et al.  Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. , 1995, Urology.

[8]  A. Pollack,et al.  Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[9]  L. Verhey,et al.  Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. , 1995, International journal of radiation oncology, biology, physics.

[10]  R. Weichselbaum,et al.  Measurement of weekly prostate specific antigen levels in patients receiving pelvic radiotherapy for nonprostatic malignancies. , 1995, International journal of radiation oncology, biology, physics.

[11]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[12]  G. Hanks,et al.  95 Phase III trial of adjuvant androgen suppression using goserelin in patients with carcinoma of the prostate treated with definitive radiotherapy (results of RTOG 85-31) , 1995 .

[13]  M. Zelefsky,et al.  Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. , 1994, The Journal of urology.

[14]  M. Zelefsky,et al.  Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. , 1994, International journal of radiation oncology, biology, physics.

[15]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[16]  B. Têtu,et al.  Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[17]  S. Cha,et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[19]  P. Schellhammer,et al.  Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. , 1993, Urology.

[20]  M Goitein,et al.  Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. , 1993, International journal of radiation oncology, biology, physics.

[21]  W. Fair,et al.  The role of neoadjuvant hormonal manipulation in localized prostatic cancer , 1993, Cancer.

[22]  G. Andriole.  Serum prostate-specific antigen: the most useful tumor marker. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Hop,et al.  Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study. , 1992, The Journal of urology.

[24]  G E Hanks,et al.  Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. , 1992, International journal of radiation oncology, biology, physics.

[25]  D. Kuban,et al.  The significance of post-irradiation prostate biopsy with long-term follow-up. , 1992, International journal of radiation oncology, biology, physics.

[26]  P. Scardino,et al.  The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. , 1991, The Journal of urology.

[27]  L. Verhey,et al.  Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. , 1991, The Journal of urology.

[28]  C B Begg,et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. , 1991, International journal of radiation oncology, biology, physics.

[29]  P. Walsh,et al.  Cancer control following anatomical radical prostatectomy: an interim report. , 1991, The Journal of urology.

[30]  A. Coldman,et al.  Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[31]  Porter At,et al.  The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer--the Canadian perspective. , 1990 .

[32]  T. Stamey,et al.  Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. , 1989, The Journal of urology.

[33]  R. Cox,et al.  Status of radiation treatment of prostate cancer at Stanford University. , 1989, NCI monographs : a publication of the National Cancer Institute.

[34]  C. Perez,et al.  Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. , 1988, NCI monographs : a publication of the National Cancer Institute.

[35]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[36]  J. Diamond,et al.  A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. , 1987, International journal of radiation oncology, biology, physics.

[37]  W. Taylor,et al.  Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. , 1986, The Journal of urology.

[38]  P. Scardino,et al.  The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. , 1986, The Journal of urology.

[39]  G E Hanks,et al.  Patterns of care studies: dose-response observations for local control of adenocarcinoma of the prostate. , 1985, International journal of radiation oncology, biology, physics.

[40]  C. Chiang,et al.  Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. , 1984, International journal of radiation oncology, biology, physics.

[41]  Cornelius A. Tobias,et al.  CHAPTER 4 – Cellular Radiation Biology , 1974 .